Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer (Q45848898)

16 December 2017

title

Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer (English)

1 reference

16 December 2017

1 reference

Yunwei Han

1

1 reference

16 December 2017

Zhihao Yu

2

1 reference

16 December 2017

Shaoyan Wen

3

1 reference

16 December 2017

Bin Zhang

4

1 reference

16 December 2017

Xuchen Cao

5

1 reference

16 December 2017

Xin Wang

6

1 reference

16 December 2017

language of work or name

English

0 references

publication date

5 October 2011

1 reference

16 December 2017

Breast Cancer Research and Treatment

published in

1 reference

16 December 2017

volume

131

1 reference

16 December 2017

issue

2

1 reference

16 December 2017

page(s)

483-490

1 reference

16 December 2017

Triple-negative breast cancer--current status and future directions

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

The leucocyte nadir, a predictor of chemotherapy efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

How to calculate the dose of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Getting the right dose in cancer chemotherapy--time to stop using surface area?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Influence of sex on toxicity and treatment outcome in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1799-1

10.1007/S10549-011-1799-1

21 January 2018

Identifiers

DOI

1 reference

16 December 2017

Dimensions Publication ID

1023771662

0 references

1 reference

16 December 2017